DDInter1042 DDInter1927
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder in adults. The immediate formulation of the drug, marketed as Effexor, was first approved by the FDA in 1993 and the extended-release formulation, Effexor XR, was later introduced in 1997. Venlafaxine has been used as a first-line treatment for MDD, GAD, social anxiety disorder, and panic disorder in Canada for many years. It was also considered a second-line treatment for obsessive-compulsive disorder (OCD).[A177226,A177235] Venlafaxine was also investigated in off-label uses for the prophylaxis of migraine headaches,[A413,A177229] for reduction of vasomotor symptoms associated with menopause, and for the management of neuropathic pain (although there is only minimal evidence of efficacy for this condition).
Venlafaxine {u} (Compound) resembles {v} (Compound) Tramadol
Venlafaxine {u} (Compound) resembles {v} (Compound) Desvenlafaxine
Venlafaxine {u} (Compound) binds {v} (Gene) NPY1R
Venlafaxine {u} (Compound) palliates {v} (Disease) panic disorder
Venlafaxine {u} (Compound) is included by {v} (Pharmacologic Class) Norepinephrine Uptake Inhibitors
Venlafaxine {u} (Compound) causes {v} (Side Effect) Yawning
Venlafaxine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Venlafaxine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenvatinib
Venlafaxine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eptifibatide
Venlafaxine {u} may lead to a major life threatening interaction when taken with {v} Procarbazine
Venlafaxine (Compound) resembles Tramadol (Compound)
Venlafaxine (Compound) resembles Desvenlafaxine (Compound)
Venlafaxine (Compound) binds NPY1R (Gene)
Venlafaxine (Compound) palliates panic disorder (Disease)
Venlafaxine (Compound) is included by Norepinephrine Uptake Inhibitors (Pharmacologic Class)
Venlafaxine (Compound) causes Yawning (Side Effect)
Venlafaxine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Eptifibatide
Venlafaxine may lead to a major life threatening interaction when taken with Procarbazine